Scarica l'app Stockscreener
3.12
8.33%
0.24
Dopo l'orario di chiusura:
3.07
-0.05
-1.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EDIT Giù?
Forum
Previsione
Precedente Chiudi:
$2.88
Aprire:
$2.86
Volume 24 ore:
2.14M
Relative Volume:
1.12
Capitalizzazione di mercato:
$256.31M
Reddito:
$78.12M
Utile/perdita netta:
$-153.22M
Rapporto P/E:
-1.0541
EPS:
-2.96
Flusso di cassa netto:
$-136.90M
1 W Prestazione:
+0.32%
1M Prestazione:
-7.69%
6M Prestazione:
-44.97%
1 anno Prestazione:
-62.45%
Intervallo 1D:
$2.79
$3.17
Intervallo di 1 settimana:
$2.70
$3.17
Portata 52W:
$2.70
$11.69
Editas Medicine Inc Stock (EDIT) Company Profile
Nome
Editas Medicine Inc
Settore
Industria
Telefono
617-401-9000
Indirizzo
11 HURLEY ST., CAMBRIDGE, MA
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-05-09 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-10-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-12 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Iniziato | Citigroup | Neutral |
| 2022-12-06 | Ripresa | Credit Suisse | Neutral |
| 2022-11-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Iniziato | BofA Securities | Neutral |
| 2021-10-19 | Iniziato | SVB Leerink | Mkt Perform |
| 2021-09-24 | Iniziato | Stifel | Hold |
| 2021-09-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Aggiornamento | Truist | Hold → Buy |
| 2021-08-05 | Aggiornamento | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Iniziato | Goldman | Sell |
| 2021-03-22 | Iniziato | Credit Suisse | Outperform |
| 2021-03-01 | Downgrade | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Downgrade | Truist | Buy → Hold |
| 2021-01-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Iniziato | Robert W. Baird | Underperform |
| 2020-06-18 | Ripresa | SunTrust | Buy |
| 2020-02-21 | Iniziato | Wells Fargo | Equal Weight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-10 | Iniziato | Guggenheim | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Outperform |
| 2018-05-15 | Reiterato | Chardan Capital Markets | Buy |
| 2018-02-13 | Iniziato | CLSA | Underperform |
| 2018-01-23 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-07-14 | Iniziato | SunTrust | Hold |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-06-02 | Iniziato | Jefferies | Hold |
| 2016-02-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-02-29 | Iniziato | JP Morgan | Neutral |
| 2016-02-29 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Editas Medicine Inc Borsa (EDIT) Ultime notizie
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT) - StreetInsider.com
Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty - GuruFocus.com
Editas Medicine maintains Perform rating at Oppenheimer By Investing.com - Investing.com UK
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y - Yahoo Finance Australia
Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Barclays - MarketBeat
Editas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings Results - MarketBeat
Editas Medicine Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Editas Medicine (EDIT) PT Lowered to $5 at Barclays - StreetInsider.com
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates - MSN
Truist cuts Editas Medicine target to $8, keeps buy rating By Investing.com - Investing.com Canada
Editas Medicine Reports Q3 2024 Results and Developments - TipRanks
Editas downgraded to market perform by Raymond James - MSN
Editas downgraded to market perform by Raymond James (NASDAQ:EDIT) - Seeking Alpha
Editas Medicine (NASDAQ:EDIT) Stock Rating Lowered by Raymond James - MarketBeat
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities - StreetInsider.com
Editas Medicine earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
Editas: Q3 Earnings Snapshot - The Washington Post
Editas Medicine Announces Third Quarter 2024 Results and Business Updates - The Manila Times
Editas Medicine stock hits 52-week low at $2.9 amid market challenges - Investing.com Australia
Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - Yahoo Finance
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Update - MarketBeat
Editas’ new gene-editing strategy for SCD shows promise in mice - Sickle Cell Disease News
In vivo editing data advances lift hopes for better access - BioCentury
FY2024 EPS Estimate for Editas Medicine Lifted by Analyst - MarketBeat
Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline - Yahoo Finance
Petri Dish: GSK partners with BU; Be Biopharma enters clinic - The Business Journals
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down - Yahoo Finance
Evercore ISI Cuts Editas Medicine (NASDAQ:EDIT) Price Target to $3.00 - MarketBeat
Expert Outlook: Editas Medicine Through The Eyes Of 7 Analysts - Benzinga
Editas Medicine achieves in vivo preclinical proof of concept of HSPC editing - BioWorld Online
Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo - StreetInsider.com
Editas advances gene editing treatment for blood disorders By Investing.com - Investing.com Australia
Editas advances gene editing treatment for blood disorders - Investing.com India
Chardan Capital Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $12.00 - MarketBeat
Possible Signal As Editas Medicine Insiders Sell US$1.2m In Stock - Simply Wall St
Baird cuts Editas Medicine target to $10 from $18 By Investing.com - Investing.com UK
Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D - MedCity News
Editas, changing course again, looks to partner lead CRISPR therapy - BioPharma Dive
Editas and Genevant team up to develop gene editing therapies - Pharmaceutical Technology
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies - Yahoo Finance
Editas stock slips on plans for gene editing drug (EDIT:NASDAQ) - Seeking Alpha
Editas Medicine Announces Progress Towards 2024 Goals, - GlobeNewswire
Editas Medicine, Inc. Announces Achievement of in Vivo Preclinical Proof of Concept - Marketscreener.com
Editas Medicine (EDIT) Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update - StreetInsider.com
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update - StockTitan
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics - GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept - The Manila Times
Editas Medicine to Host Strategic Update Webinar to Detail - GlobeNewswire
Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, ... - The Bakersfield Californian
State Street Corp's Strategic Reduction in Editas Medicine Inc H - GuruFocus.com
Editas Medicine Inc Azioni (EDIT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):